A pooled meta-analysis of PD-1/L1 inhibitors incorporation therapy for advanced non-small cell lung cancer

Objective: Immune checkpoint inhibitors, especially the programmed cell death receptor-1/ligand 1 (PD-1/L1) inhibitors, displayed promising efficacy in non-small cell lung cancer (NSCLC) patients. Incorporation of anti-PD-1/L1 antibodies into other therapeutic regimens (including CTLA-4 inhibitors,...

Descripción completa

Detalles Bibliográficos
Autores principales: Wan, Ning, Ji, Bo, Li, Jian, Jiang, Jie, Yang, Chen, Zhang, Tiantian, Huang, Wenjie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6604807/
https://www.ncbi.nlm.nih.gov/pubmed/31303759
http://dx.doi.org/10.2147/OTT.S200615

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6604807/
https://www.ncbi.nlm.nih.gov/pubmed/31303759
http://dx.doi.org/10.2147/OTT.S200615

Ejemplares similares